Lumos Diagnostics Director Increases Shareholding
Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Lumos Diagnostics Holdings Ltd. has reported a change in Director Sam Lanyon’s interest, with an on-market acquisition of 250,000 fully paid ordinary shares at a total value of $7,500. This transaction, dated June 7, 2024, increases Lanyon’s indirect holdings in the company, via accounts where he is a beneficiary, to 591,401 shares, alongside 2,246,500 unquoted options.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.